https://www.selleckchem.com/pr....oducts/elacridar-gf1
137 D which is close to the IOL manufacturer tolerance. These estimates are validated out-of-sample and thus are expected to reflect the future performance of our prediction formula, especially since our data were collected from a wide variety of patients, clinics, and manufacturers. Conclusion The increased precision of IOL power calculations has the potential to optimize patient positive refractive outcomes. Our model also provides uncertainty plots that can be used in tandem with the clinician's expertise and previous form
Like
Comment
Share
